Atlas Trials

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Clinical trial NCT00464321 · COMPLETED

Trial details

NCT number
NCT00464321
Sponsor
Genzyme, a Sanofi Company
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Focal Segmental Glomerulosclerosis
Start date
2007-05-01
Primary completion
2010-01-01
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.